Canbex Therapeutics

London, United Kingdom Founded: 2005 • Age: 21 yrs Acquired By Ipsen
Small molecule drugs for spasticity in multiple sclerosis are developed.

About Canbex Therapeutics

Canbex Therapeutics is a company based in London (United Kingdom) founded in 2005 was acquired by Ipsen in February 2015.. Canbex Therapeutics has raised $3.2 million across 1 funding round from investors including Merck and Ipsen. The company has 1 employees as of January 31, 2022. Canbex Therapeutics operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.

  • Headquarter London, United Kingdom
  • Employees 1 as on 31 Jan, 2022
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Legal Name Canbex Therapeutics Limited
  • Date of Incorporation 15 Mar, 2004
  • Jurisdiction LONDON, ENGLAND
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $3.2 M (USD)

    in 1 rounds

  • Latest Funding Round
    $3.2 M (USD), Series A

    Apr 08, 2013

  • Investors
    Merck

    & 1 more

  • Employee Count
    1

    as on Jan 31, 2022

  • Acquired by
    Ipsen

    (Feb 24, 2015)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Canbex Therapeutics

Canbex Therapeutics has successfully raised a total of $3.2M through 1 strategic funding round. The most recent funding activity was a Series A round of $3.2 million completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $3.2M
  • First Round

    (08 Apr 2013)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2013 Amount Series A - Canbex Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Canbex Therapeutics

Canbex Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Merck and Ipsen. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Merck is engaged in science and technology solutions globally.
Founded Year Domain Location
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Canbex Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Canbex Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Canbex Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Canbex Therapeutics

Canbex Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
domain founded_year HQ Location
Developer of antibodies to treat complement-mediated neurodegenerative diseases
domain founded_year HQ Location
Biologics platform developed for intracellular delivery in rare diseases.
domain founded_year HQ Location
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
domain founded_year HQ Location
T-cell-based therapies for autoimmune and degenerative diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Canbex Therapeutics

Frequently Asked Questions about Canbex Therapeutics

When was Canbex Therapeutics founded?

Canbex Therapeutics was founded in 2005 and raised its 1st funding round 8 years after it was founded.

Where is Canbex Therapeutics located?

Canbex Therapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

Is Canbex Therapeutics a funded company?

Canbex Therapeutics is a funded company, having raised a total of $3.2M across 1 funding round to date. The company's 1st funding round was a Series A of $3.2M, raised on Apr 08, 2013.

How many employees does Canbex Therapeutics have?

As of Jan 31, 2022, the latest employee count at Canbex Therapeutics is 1.

What does Canbex Therapeutics do?

Canbex Therapeutics was established in 2005 as a spin-out from University College London, based in London, United Kingdom. Proprietary VSN compound series small molecules are developed by the company for spasticity and other neurological disorders. The lead compound, VSN16R, an orally active agent, is undergoing phase 2 testing for spasticity relief in multiple sclerosis patients. An option agreement for acquisition by Ipsen was entered in February 2015.

Who are the top competitors of Canbex Therapeutics?

Canbex Therapeutics's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.

Who are Canbex Therapeutics's investors?

Canbex Therapeutics has 2 investors. Key investors include Merck, and Ipsen.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available